Non-Surgical Treatment for Low-Risk BCC When Surgical Excision Did Not Achieve Clear Margins
This protocol addresses superficial basal cell carcinoma (low-risk) and low-risk nodular basal cell carcinoma in patients where the preceding standard surgical excision did not deliver histologically tumour-free margins, requiring a subsequent therapeutic approach.
Previous Treatment — Trigger for Escalation
The prior step — standard surgical excision with 2D histology and a 3–4 mm safety margin of clinically uninvolved tissue — did not achieve its required outcome: histologically tumour-free surgical margins (complete excision). This failure is the clinical trigger for the current protocol.
Treatment Approach (Partial Overview)
For the low-risk lesion, non-surgical strategies are available — encompassing destructive techniques, topical medical therapies, and light-based treatment. Which option applies, how it is selected, and the full sequencing are contained in the complete protocol.
Goal: Clinical clearance of the tumour with no residual basal cell carcinoma
References
DOI: 10.1016/j.ejca.2023.113254
- Topical therapies and destructive approaches can be considered in patients with low-risk superficial BCC.
- Photodynamic therapy is an effective treatment for superficial and low-risk nodular BCCs.
- Topical or destructive (blind) treatments can be considered for low-risk superficial and nodular BCC in patients declining surgery or not amenable to surgery.
- Curettage ± electrodesiccation and cryotherapy may be alternative treatments for small, low-risk BCC.
- Topical 5% imiquimod should be used in the treatment of primary superficial and small nodular BCC.
- Imiquimod is an immune response modifier indicated for the treatment of sBCC in immunocompetent adults, applied once daily, five times per week for 6 weeks.
- Topical 5% 5-FU should be used for the treatment of superficial BCC.
- The 5% formulation of the antimetabolite 5-FU is licenced for the treatment of sBCC with two applications daily for 3–6 weeks.
- Photodynamic therapy using 5-ALA or MAL in combination with red light should be used for the treatment of superficial and low-risk nodular BCC.
- Treatment consists of two sessions 1 week apart.
- For nodular BCC treated by MAL-PDT, 91% were clinically clear at 3 months, with a sustained lesion clearance response rate of 76% after 5 years of follow-up.
View source ↗